Case-Based Review

Stage III Non–Small Cell Lung Cancer


 

Series Editor: Arthur T. Skarin, MD, FACP, FCCP

Each year approximately 228,000 Americans will be diagnosed with lung cancer, and 159,000 will die of this disease. An estimated 85% of lung cancer cases are non–small cell lung cancer (NSCLC), more than 50% of NSCLC is comprised of adenocarcinoma, the median age at diagnosis is 71 years, and 25% of patients with this diagnosis present with stage III disease. In 2010 the seventh edition of the American Joint Committee on Cancer (AJCC) TNM staging system for lung cancer was released, and several changes were made which affect the patient population designated as having stage III disease.

To read the full article in PDF:

Click here

Recommended Reading

Long-term data allay concerns about using SBRT to treat early lung cancer
MDedge Hematology and Oncology
The art and science of cancer care
MDedge Hematology and Oncology
FDG-PET no help in differentiating cancer from benign lung nodules in infection-endemic regions
MDedge Hematology and Oncology
Thoracic radiotherapy improves outcomes in patients with extensive small cell lung cancer
MDedge Hematology and Oncology
VIDEO: Lung-MAP charts new ground in trial design
MDedge Hematology and Oncology
Adjuvant vaccine fails in NSCLC
MDedge Hematology and Oncology
Quality of supportive care for patients with advanced lung cancer in the Veterans Health Administration
MDedge Hematology and Oncology
Hippocampus-sparing brain radiotherapy preserves memory, QOL
MDedge Hematology and Oncology
Aggressive radiotherapy dramatically improves limited metastatic NSCLC
MDedge Hematology and Oncology
VIDEO: Nonclinical factors affect lung resection survival
MDedge Hematology and Oncology